What is ONCOCYTE CORP share price today?

ONCOCYTE CORP (OCX) share price today is {{live_price}}.

Can Indians buy ONCOCYTE CORP shares?

Yes, Indians can invest in the ONCOCYTE CORP (OCX) from India. With INDmoney, you can buy ONCOCYTE CORP at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy ONCOCYTE CORP at zero transaction cost.

How can I buy ONCOCYTE CORP shares from India?

It is very easy to buy ONCOCYTE CORP from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of ONCOCYTE CORP be purchased?

Yes, you can buy fractional shares of ONCOCYTE CORP with INDmoney app.

What are the documents required to start investing in ONCOCYTE CORP stocks?

To start investing in ONCOCYTE CORP, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of ONCOCYTE CORP

Today’s highest price of ONCOCYTE CORP (OCX) is {{1_rba_end}}. Today’s lowest price of ONCOCYTE CORP (OCX) is {{1_rba_st}}.

What is today's market capitalisation of ONCOCYTE CORP

Today's market capitalisation of ONCOCYTE CORP OCX is 36.2M

What is the 52 Week High and Low Range of ONCOCYTE CORP

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage ONCOCYTE CORP is down from its 52 Week High?

ONCOCYTE CORP (OCX) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage ONCOCYTE CORP is up from its 52 Week low?

ONCOCYTE CORP (OCX) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of ONCOCYTE CORP?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of ONCOCYTE CORP

Dr. Douglas T. Ross M.D., Ph.D. is the current Chief Executive Officer (CEO) of ONCOCYTE CORP.

Home

US Stocks

ONCOCYTE CORP

ONCOCYTE CORP (OCX)

$0.2196

-0.01

(-3.56%)▲

Market is closed - opens 7 PM, 05 Jun 2023

Insights on ONCOCYTE CORP

Decreasing Revenue
Revenue is down for the last 4 quarters, 2.06M → -3.55M (in $), with an average decrease of 166.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -8.3M → -44.97M (in $), with an average decrease of 131.5% per quarter
Vs IDXX
In the last 1 year, Idexx Laboratories, Inc. has given 21.6% return, outperforming this stock by 99.9%
Vs IDXX
In the last 3 years, Idexx Laboratories, Inc. has given 48.5% return, outperforming this stock by 139.9%

Performance

$0.21
$0.23
$0.22
4.55%
Downside
Day's Volatility :7.16%
Upside
2.74%
$0.20
$1.35
$0.22
9.09%
Downside
52 Weeks Volatility :85.19%
Upside
83.7%

Returns

Period	ONCOCYTE CORP	Sector (Health Care)	Index (Russel 2000)
3 Months	-37.1%	0.7%	-7.0%
6 Months	-54.35%	-7.9%	-6.5%
1 Year	-78.31%	-2.0%	-6.8%
3 Years	-91.41%	25.4%	24.7%

Highlights

Market Capitalization	36.2M
Book Value	$0.32
Dividend Share	0.0
Dividend Yield	0.0%
Earnings Per Share (EPS)	-0.09
PEG Ratio	0.0
Wall Street Target Price	0.35

Profit Margin	0.0%
Operating Margin TTM	-3129.37%

Return On Assets TTM	-14.94%
Return On Equity TTM	-18.4%

Revenue TTM	875.0K
Revenue Per Share TTM	0.01
Quarterly Revenue Growth YOY	-21.8%
Gross Profit TTM	188.0K
EBITDA	-22.9M
Diluted Eps TTM	-0.09
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	-0.13
EPS Estimate Next Year	-0.2
EPS Estimate Current Quarter	-0.08
EPS Estimate Next Quarter	-0.05

Analyst Recommendation

Buy

55%Buy

44%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for ONCOCYTE CORP(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 59.38%

Current $0.22

Target $0.35

Technicals Summary

Sell

Neutral

Buy

ONCOCYTE CORP is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
ONCOCYTE CORP	-15.01%	-54.35%	-78.31%	-91.41%	-91.41%
IDEXX Laboratories, Inc.	0.53%	7.93%	21.61%	48.46%	114.73%
Agilent Technologies Inc.	-13.57%	-25.32%	-9.95%	28.76%	83.43%
Thermo Fisher Scientific, Inc.	-4.49%	-7.75%	-8.9%	48.36%	142.51%
Danaher Corp.	-4.16%	-15.15%	-14.85%	39.37%	128.42%
IQVIA Holdings Inc.	7.2%	-8.62%	-9.58%	31.31%	96.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
ONCOCYTE CORP	NA	NA	0.0	-0.13	-0.18	-0.15	0.0	0.32
IDEXX Laboratories, Inc.	56.2	56.2	7.21	9.69	0.94	0.22	0.0	10.13
Agilent Technologies Inc.	26.91	26.91	2.36	5.63	0.25	0.1	0.01	18.96
Thermo Fisher Scientific, Inc.	33.19	33.19	4.28	23.68	0.14	0.05	0.0	109.55
Danaher Corp.	24.72	24.72	3.24	9.38	0.14	0.06	0.0	68.31
IQVIA Holdings Inc.	35.16	35.16	1.48	10.42	0.18	0.05	0.0	31.98

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
ONCOCYTE CORP	Buy	$36.2M	-91.41%	NA	0.0%
IDEXX Laboratories, Inc.	Buy	$38.6B	114.73%	56.2	20.38%
Agilent Technologies Inc.	Buy	$35.3B	83.43%	26.91	19.09%
Thermo Fisher Scientific, Inc.	Buy	$196.1B	142.51%	33.19	13.75%
Danaher Corp.	Buy	$169.4B	128.42%	24.72	22.4%
IQVIA Holdings Inc.	Buy	$36.5B	96.53%	35.16	7.28%

Institutional Holdings

BROADWOOD CAPITAL Inc
14.19%
PURA VIDA INVESTMENTS, LLC
10.97%
Awm Investment Company Inc
4.41%
Vanguard Group Inc
2.65%
Defender Capital, LLC.
1.44%
BlackRock Inc
0.86%

Corporate Announcements

ONCOCYTE CORP Earnings
ONCOCYTE CORP’s price-to-earnings ratio stands at None
Read More

Company Information

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

Organization	ONCOCYTE CORP
Employees	75
CEO	Dr. Douglas T. Ross M.D., Ph.D.
Industry	Health Technology

ONCOCYTE CORP (OCX)

Insights on ONCOCYTE CORP

Decreasing Revenue

Decreasing Net Profit

Vs IDXX